Commentary

JCP
Benefits and Risks of New Tests for Alzheimer’s Disease
Commentary

April 14, 2025

The authors discuss the limitations and the potential value of blood-based biomarker testing in the detection and diagnosis of Alzheimer’s disease.
,
JCP
Investigation of Appetite Hormones Illustrates Current Limitations of Psychiatric Diagnosis
Commentary

April 9, 2025

Commenting on an article by Hsu and colleagues, Dr Mischoulon discusses the current state and future potential of biomarkers in the understanding and treatment of mood disorders.
JCP
Eating Disorders Among Transgender and Gender Diverse People: Qualitative Analysis of Reddit Threads
Commentary

March 10, 2025

This subreddit analysis characterizes the body dissatisfaction and desire to eliminate gendered physical characteristics that transgender and gender diverse (TGD) people with eating disorders experience. Many on the subreddit...
, ,
JCP
A New Tool to Refine Lithium Therapy: Simple Formula for a Complex Problem
Commentary

March 3, 2025

The authors consider potential benefits and limitations of a new equation for estimating 12-hour serum lithium levels.
, ,
JCP
Back to the Office: The Room Where It Happens?
Commentary

March 3, 2025

The authors discuss in-person versus remote delivery of psychotherapy and present the findings of a survey characterizing current practice.
, , , et al
JCP
Xanomeline-Trospium Tolerability: Commentary
Commentary

February 26, 2025

The author discusses new findings from Kaul et al on the safety and tolerability of xanomeline-trospium.
JCP
Evolving Care and Research Priorities in ADHD
Commentary

December 23, 2024

Surman and Wilens discuss two recent JCP articles highlighting that how ADHD manifests can be heavily influenced by context, as well as individual vulnerabilities and strengths.
,
JCP
The Opioid Industry's Legacy: A Generation of Prescribed Suffering
Commentary

December 18, 2024

The authors discuss the influential and far-reaching effects of messaging from the opioid industry on the opioid use epidemic.
,
JCP
SUD Programs for Transgender and Gender Diverse Patients
Commentary

November 11, 2024

The authors discuss responsiveness of transgender and gender diverse patients to SUD treatment at different care levels (eg, outpatient, residential, inpatient), as well as how to reduce stressors and...
,
JCP
Clinical Implications of Adult ADHD: What New Data Tell Us
Commentary

October 10, 2024

The authors discuss striking new findings from the Morbidity and Mortality Weekly Report on the burden of adult ADHD, demonstrating the need for the upcoming APSARD Adult ADHD Guidelines.
,
JCP
Reproductive Pharmacovigilance and Best Practices
Commentary

August 26, 2024

Dr Freeman discusses a recent study by Pacilio et al that characterized real world practices around ketamine treatment and pregnancy testing, consent processes, and contraception use. She emphasizes the...
JCP
Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
Commentary

August 21, 2024

Dr Rosenbaum comments on the challenge of evaluating trials of treatments whose effects are unmistakable, and how this dilemma may be addressed.
JCP
Can Our Collective Experiences As Clinicians Improve Mental Health Care?
Commentary

July 17, 2024

Drs Rush and Tramontin discuss how simple outcomes, often patient reported, could facilitate evidence-based decision making by clinicians, administrators, and payors and provide the foundation for a learning health...
,
JCP
Extreme Dysphoria of Pregnancy: A Distinct Syndrome Warranting Attention?
Commentary

June 10, 2024

Dr Freeman discusses the understudied phenomenon of pregnancy-related extreme dysphoria or depression, distinct from typical major depressive episodes. Three illustrative case vignettes are presented.
JCP
Sleep Alterations as Proximal Markers for Suicide Risk
Commentary

June 3, 2024

Dr Geoffroy discusses recent research exploring the links between suicide and sleep disturbances.
JCP
Co-occurrence of Depression and Obesity: Implications for Practice and the Discovery of Targeted and Mechanistically Informed Therapeutics
Commentary

June 3, 2024

Dr McIntyre discusses the implications of recent research by Baek et al.
JCP
The Long Road Toward Equitable MDMA Treatment in the United States
Commentary

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.
,
JCP
Enhancing Postpartum Psychosis Care
Commentary

May 29, 2024

The authors discuss the need for qualitative research to fill gaps in the current understanding of postpartum psychosis, as well as the barriers that make conducting this research a...
, , , et al
JCP
How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life Years in Social Anxiety Disorder
Commentary

May 27, 2024

The authors discuss a recent intriguing study published in JCP by Patel et al.
,
JCP
Psychosis, Inflammatory Biomarkers, and Subtypes of Childhood Trauma
Commentary

May 22, 2024

Dr Nasrallah discusses a recent study by Cuñat et al of the relationship between childhood trauma and inflammation, and why this work is unique and important.
JCP
Valproate and Weight Gain: A New Look at an Old Problem
Commentary

March 27, 2024

Dr Goldberg comments on a recent cohort study demonstrating a dose relationship with weight gain liability for valproate.
JCP
What Does a Systematic Review of Cannabis and PTSD Tell Us? That We Need to Learn More
Commentary

February 14, 2024

Dr Ostacher discusses a review by Rodas et al and points to a need for clear answers on how best to advise patients with PTSD and other psychiatric illness...
JCP
Enriching the Assessment of Suicidal Ideation
Commentary

January 17, 2024

The processes involved in the generation of suicidal ideation (SI) can be distinguished from those involved in the acts themselves. This commentary notes that the rise of digital health...
,
JCP
The Psychological Burden of ALS, the Enduring Strength of People Living With ALS, and the Tools We Can Use to Help
Commentary

December 13, 2023

Commenting on a recent article by Lester et al, the authors discuss the psychological impacts of diagnosis, genetic testing, and disease progression on patients with amyotrophic lateral sclerosis (ALS).
,

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe